Thiol-mediated catalysis of nitroglycerin degradation by serum proteins. Increase in metabolism was not accompanied by S-nitrosothiol production
- PMID: 1970779
Thiol-mediated catalysis of nitroglycerin degradation by serum proteins. Increase in metabolism was not accompanied by S-nitrosothiol production
Abstract
In vitro degradation of nitroglycerin (NTG) in human plasma has been shown to be accelerated significantly by sulfhydryl compounds. The interaction between NTG and N-acetyl-1-cysteine (NAC) in human plasma produces a pharmacologically active S-nitrosothiol, which may be responsible, at least in part, for the in vivo nitrate tolerance-reversing effect of NAC. The mechanism of this thiol-mediated NTG degradation in plasma has not been identified. In this report, we examined the catalytic activity of various plasma proteins toward NAC-mediated NTG degradation and found human serum albumin (HSA) to have the highest catalytic activity among the proteins tested. However, the dinitrate metabolite distribution ratio found with HSA (favoring the 1,3- over the 1,2-isomer) was substantially different from that observed with human plasma (where equal amounts of both dinitrates were produced). In addition, the HSA-catalyzed degradation of NTG did not lead to enhanced formation of S-nitrosothiol. These findings therefore argue against a predominant role exerted by HSA in the thiol-mediated NTG metabolism in plasma. The HSA-mediated catalysis of NTG was partially blocked by pretreatment with NAC followed by a thiol-alkylating agent, suggesting that the catalytic mechanism was due, in part, to the conversion of disulfide linkages within the HSA structure to reactive sulfhydryl groups.
Similar articles
-
Differential hemodynamic effects and tolerance properties of nitroglycerin and an S-nitrosothiol in experimental heart failure.J Pharmacol Exp Ther. 1991 Jan;256(1):249-54. J Pharmacol Exp Ther. 1991. PMID: 1899118
-
Biochemical and pharmacological interactions between nitroglycerin and thiols. Effects of thiol structure on nitric oxide generation and tolerance reversal.Biochem Pharmacol. 1991 Sep 12;42(7):1433-9. doi: 10.1016/0006-2952(91)90456-f. Biochem Pharmacol. 1991. PMID: 1930267
-
In vivo depletion of free thiols does not account for nitroglycerin-induced tolerance: a thiol-nitrate interaction hypothesis as an alternative explanation for nitroglycerin activity and tolerance.J Pharmacol Exp Ther. 1996 Sep;278(3):1296-305. J Pharmacol Exp Ther. 1996. PMID: 8819515
-
Thiol compounds and organic nitrates.Dan Med Bull. 1995 Nov;42(5):473-84. Dan Med Bull. 1995. PMID: 8747803 Review.
-
Sulfenic acid--a key intermediate in albumin thiol oxidation.J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Oct 15;877(28):3384-92. doi: 10.1016/j.jchromb.2009.03.035. Epub 2009 Mar 28. J Chromatogr B Analyt Technol Biomed Life Sci. 2009. PMID: 19386559 Review.
Cited by
-
NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties.J Clin Invest. 1993 Apr;91(4):1582-9. doi: 10.1172/JCI116364. J Clin Invest. 1993. PMID: 8473501 Free PMC article.
-
Vascular and anti-platelet actions of 1,2- and 1,3-glyceryl dinitrate.Br J Pharmacol. 1993 Nov;110(3):937-42. doi: 10.1111/j.1476-5381.1993.tb13903.x. Br J Pharmacol. 1993. PMID: 8298817 Free PMC article.
-
In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols.J Clin Invest. 1994 Oct;94(4):1432-9. doi: 10.1172/JCI117480. J Clin Invest. 1994. PMID: 7929818 Free PMC article.
-
Mechanisms of action of nitrates.Cardiovasc Drugs Ther. 1994 Oct;8(5):701-17. doi: 10.1007/BF00877117. Cardiovasc Drugs Ther. 1994. PMID: 7873467 Review.
-
Antiplatelet activities of FK409, a new spontaneous NO releaser.Br J Pharmacol. 1994 Oct;113(2):385-8. doi: 10.1111/j.1476-5381.1994.tb17000.x. Br J Pharmacol. 1994. PMID: 7834188 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources